AL 78898A
Alternative Names: AL-78898A; Compstatin analogue; POT-4Latest Information Update: 15 Apr 2019
Price :
$50 *
At a glance
- Originator University of Pennsylvania
- Developer Alcon
- Class Cyclic peptides; Eye disorder therapies
- Mechanism of Action Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Dry age-related macular degeneration
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 23 Nov 2014 Apellis Pharmaceuticals enters into an agreement to acquire Potentia Pharmaceuticals
- 15 Nov 2012 Alcon terminates a phase II trial for geographic atrophy associated with Age-related macular degeneration in USA (NCT01603043)